Xinhua News Agency, Tokyo, November 17 (Reporter Hua Yi) Kitasato Research Institute of Japan and Kao Corporation announced on the 16th that the use of VHH antibodies to treat mice infected with the new coronavirus has been successful, which means that this will be implemented by nasal administration.
There is a natural heavy chain antibody lacking the light chain in camels.
A research team composed of Kitasato Research Institute and Kao Corporation discovered in May last year a VHH antibody that has an infection-inhibiting (neutralizing effect) against the new coronavirus
At the same time, the team conducted related experiments using human alveolar organoids called "microorgans" and further confirmed the effect of this treatment plan
According to the press release, this research result reveals that VHH antibodies can be used as drugs for the treatment of new coronavirus infections, and nasal administration can make the drugs reach the nasopharyngeal, oral cavity and other early virus proliferation sites and the lungs, helping to improve treatment Efficiency
Related research papers have been published in the journal "Public Library of Science · Pathogens" in the United States
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
